Showing results (41-50 of 73) with videos related to
Sort By:
Pageof 8
NPJ Precision Oncology|December 9, 2022
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumorsJessica K Lee, Smruthy Sivakumar, Alexa B Schrock, et al.The Journal of Molecular Diagnostics : JMD|August 25, 2019
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient SamplesSally E Trabucco, Kyle Gowen, Sophia L Maund, et al.Journal for Immunotherapy of Cancer|January 21, 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapyJianda Yuan, Priti S Hegde, Raphael Clynes, et al.Frontiers in Oncology|August 21, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assayThomas Powles, Amanda Young, Halla Nimeiri, et al.Nature Medicine|October 7, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.Plos Biology|December 24, 2003
Detection and characterization of cellular immune responses using peptide-MHC microarraysYoav Soen, Daniel S Chen, Daniel L Kraft, et al.Nature Immunology|January 31, 2006
T cells use two directionally distinct pathways for cytokine secretionMorgan Huse, Björn F Lillemeier, Michael S Kuhns, et al.Nature Medicine|June 6, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDavid F McDermott, Mahrukh A Huseni, Michael B Atkins, et al.Nature Medicine|August 8, 2018
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R Gandara, Sarah M Paul, Marcin Kowanetz, et al.Cancer Cell|November 6, 2020
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis BlockadeRobert J Motzer, Romain Banchereau, Habib Hamidi, et al.Pageof 8